Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myeloma
•
Hematology
What is your approach to first-line treatment of light chain deposition disease?
Do you treat similar to Amyloid, e.g. with Dara-CyBor-D
Related Questions
How do you modify Daratumumab-RVD relative to the protocols used in trials when used as a first-line agent to transplant-eligible patients with myeloma?
What are alternative myeloma therapies for patients who are unable to afford lenalidomide or oral cyclophosphamide due to gaps in prescription drug coverage?
What post-auto maintenance therapy do you recommend for patients with high-risk multiple myeloma?
How do you approach post-transplant maintenance for patients with high-risk myeloma?
How would you approach a patient with solitary plasmacytoma with an FLC ratio >100, but a negative bone marrow biopsy and negative PET-CT?
How do you utilize immunoglobulin testing to affect treatment decisions in patients with myeloma?
Does the presence of osteoporosis change the extent of workup that should be performed for an older patient with otherwise serologically low-risk MGUS?
Is a bone marrow biopsy necessary in a patient with a previous tissue diagnosis of plasmacytoma or smoldering multiple myeloma, who now meets criteria for active myeloma?
How is monoclonal gammopathy of renal significance (MGRS) different from myeloma kidney?
How do you discuss harms of MGUS screening with other medical providers?
